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Our opportunity to respond to the letter by Inchiosa allows
us to expand upon and update a number of important points
that were not fully addressed in our paper ‘Multinutrient
supplement containing ephedra and caffeine causes weight
loss and improves metabolic risk factors in obese women: a
randomized controlled trial’.1 Inchiosa correctly points out
that our study tested the effect of a high-potency mixture of
vitamins, minerals, omega-3 fatty acids and botanical
extracts including ephedra and caffeine, against a control
formula containing 100% of the Daily Value of vitamins and
minerals. This is indeed a controlled study design that has
been used in numerous other studies assessing ephedra and
caffeine, and our title, introduction and conclusions very
carefully note the multinutrient formula that was tested,
rather than drawing conclusions regarding only the effects of
ephedra and caffeine.
We believe that it is unlikely that a Garcinia cambogia
extract containing ()-hydroxycitric acid (HCA) could have
accounted for approximately 60% of the weight loss noted in
our results. While a few studies suggest that HCA can reduce
food intake or promote weight loss,2 a number of other stu-
dies have produced negative results.3–5 One of us (PJH) has
recently completed a double-blind, placebo-controlled study
in overweight/obese men and women, administering HCA
(2700 mg/day) plus chromium polynicotinate (400 mg/day)
for 12 weeks. No differences were measured in appetite,
energy intake, body weight or body composition (personal
communication), suggesting a minimal contribution of
HCA, if any, to the body weight and body fat loss reported
in the current study.
It is correctly noted that the treatment group had a
significantly higher baseline body weight than the control
group, although all participants were randomly assigned at
the inception of the study in a double-blind manner. We do
not think this initial difference accounts for the substantial
differences in body weight and body fat loss noted at the end
of the study. While differences in the reported daily energy
intake at baseline between the two groups are duly noted,
one must be skeptical of self-reported diet records, which
give at best a rough estimate of a person’s true energy intake.
Indeed, we note that numerous self reports from our
participants showed an unusually low estimation of energy
intake (twoo2512 kJ/day (o600 kcal/day) and sixo4186 kJ/
day (o1000 kcal/day)), which raises doubt regarding the
accuracy of the baseline energy intake measurements.
The issue of palpitations was considered very carefully by
the study physicians and authors. Self-reported symptoms
from all participants were noted and graded by one of us
(HJS) as mild, moderate or severe. All reports of palpitations
were minor, and none of them persisted more than a few
days. At no point was any participant removed from the
study as a result of these symptoms. Electrocardiograms were
obtained regularly on all participants, read (blindly) by one
of us (JCR; a board-certified cardiologist) and none of the
readings showed any patterns that caused concern. Palpita-
tions are a well-known side effect of ephedra and caffeine,
but at the doses used in our study, they seemed to subside
and disappear after a brief period. Our observation is
consistent with tachyphylaxis of this effect and with other
studies on ephedrine/ephedra and caffeine previously pub-
lished in this journal.6,7
Statements about the legal and regulatory status of dietary
supplements containing ephedra and caffeine contained in
our paper were accurate in March 2006, at the time of its
online publication. Subsequent to the online publication, on
17 August 2006, the Tenth US Circuit Court of Appeals
upheld the FDA’s position that unregulated sale of supple-
ments containing ephedra and caffeine posed a public health
risk. Most recently, a petition was filed asking the US
Supreme Court to review the Tenth Circuit Court of Appeals
ruling on 3 January 2007,8 thus this is still an evolving issue.
Regardless of the next legal decision, it is important to note
that the FDA’s decision was based on unregulated use that
enabled anyone to freely obtain ephedra and caffeine even if
its use was contraindicated by existing medical conditions,
and to consume these supplements in uncontrolled
amounts. A viable alternative to unrestricted use would be
the regulated use of ephedra and caffeine by prescription
with proper physician monitoring, which in our opinion
remains a viable option to debate.
Table 1 Summary of meta-analysis of weight loss drugs
Agent Duration
(months)
Number of
studies
Mean weight loss
(kg) from meta-
analysis
95% CI range
(kg)
Sibutramine 12 5 4.45 3.6 to 5.3
Orlistat 12 22 2.89 2.3 to 3.5
Phentermine 6 6 3.60 0.6 to 6.0
Bupropion 12 3 2.77 1.1 to 4.5
Abbreviation: CI, confidence interval.
Adapted from Li et al.9
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Lastly, we disagree with Inchiosa’s assertion that ‘it would
appear difficult to conclude that this prescription represents
a useful option for the treatment of obesity.’ Table 1
summarizes a recent meta-analysis of the currently approved
medications used for the treatment of obesity and the range
of weight loss associated with each.9 Many of these studies
included a low-calorie diet in addition to the medication. In
our 9-month study, participants were asked not to alter their
normal dietary patterns or to change their physical activity
levels. The mean weight loss in the treatment group (7.61 kg;
95% confidence interval: 5.3–9.7 kg) is greater than the
means noted for any of the drugs. While it is inappropriate
to compare a single study to a larger number of studies
investigating the effects of pharmaceutical agents, our results
suggest that further studies of dietary supplements contain-
ing ephedra and caffeine are warranted. Rather than dismiss
a modest level of ephedra and caffeine, combined with
vitamins, minerals and omega-3 fatty acids, as not useful for
the treatment of obesity, additional studies are needed to
determine if such an approach, prescribed and monitored by
a physician, can safely and effectively be employed as one
aspect of addressing the current obesity epidemic.
RM Hackman1, PJ Havel1, HJ Schwartz2, JC Rutledge2,
SJ Stohs3, JS Stern1,2 and CL Keen1,2
1Department of Nutrition, University of California, Davis, CA,
USA; 2Department of Internal Medicine, University of California,
Davis, CA, USA and 3Department of Pharmacy Science,
Creighton University, Omaha, NE, USA
E-mail: rmhackman@ucdavis.edu
References
1 Hackman RM, Havel PJ, Schwartz HJ, Rutledge JC, Watnik MR,
Noceti EM et al. Multinutrient supplement containing ephedra
and caffeine causes weight loss and improves metabolic risk factors
in obese women: a randomized controlled trial. Int J Obes Relat
Metab Disord 2006; 30: 1545–1556.
2 Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S.
Effects of a natural extract of ()-hydroxycitric acid (HCA-SX) and
a combination of HCA-SX plus niacin-bound chromium and
Gymnema sylvestre extract on weight loss. Diabetes Obes Metab
2004; 6: 171–180.
3 Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D,
Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential
antiobesity agent: a randomized controlled trial. JAMA 1998; 280:
1596–1600.
4 Mattes RD, Bormann L. Effects of ()-hydroxycitric acid on
appetitive variables. Physiol Behav 2000; 71: 87–94.
5 Kovacs EM, Westerterp-Plantenga MS, de Vries M, Brouns F, Saris
WH. Effects of 2-week ingestion of ()-hydroxycitrate and (-)-
hydroxycitrate combined with medium-chain triglycerides on
satiety and food intake. Physiol Behav 2001; 74: 543–549.
6 Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and
safety of an ephedrine/caffeine compound compared to ephe-
drine, caffeine and placebo in obese subjects on an energy
restricted diet. A double blind trial. Int J Obes Relat Metab Disord
1992; 16: 269–277.
7 Boozer CN, Daly PA, Homel P, Soloman JL, Blanchard D, Nasser JA
et al. Herbal ephedra/caffeine for weight loss: a 6-month
randomized safety and efficacy trial. Int J Obes Relat Metab Disord
2002; 26: 593–604.
8 Nutraceutical Corporation files Petition for Writ of Certiorari
asking US. Supreme Court to Review 10th Circuit Ephedra Decision.
Available at http://www.emord.com/pressrelease/010307 Accessed
14 January 2007.
9 Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR
et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern
Med 2005; 142: 532–546.
Letter to the Editor
1483
International Journal of Obesity
